title: Effect of nebivolol on endothelial dysfunction in patients with Behçet's disease; a prospective single-arm controlled study.
abstract: OBJECTIVE
  Behçet's disease (BD) is a systemic vasculitis, capable of involving all types of vessels. Endothelial dysfunction (ED) has been previously documented in BD. Previous studies showed that nebivolol might improve endothelial functions in endothelial dysfunction. The aim of our study is to assess the effects of nebivolol on endothelial dysfunction in patients with Behçet's disease.
  
  
  METHODS
  This study was designed as prospective single-arm controlled study. We prospectively studied 35 Behçet's patients who were diagnosed according to the International Study Group criteria. Patients received 5 mg nebivolol per day for 3 months. Endothelial dysfunction was evaluated by brachial artery flow-mediated dilatation (FMD) method using high-resolution vascular ultrasound device at baseline and after for 3-month therapy. The paired samples t test, Wilcoxon test, Pearson, Spearman correlation analyses were used for statistical analysis.
  
  
  RESULTS
  A significant improvement was observed in FMD after therapy period (4.23±1.19 vs 7.95±2.21%, p<0.001). The correlation analysis showed a negative correlation between post-treatment high-sensitive C-reactive protein and FMD (r=-0.435, p=0.009). No adverse effects were observed in treatment period.
  
  
  CONCLUSIONS
  Nebivolol improved endothelial dysfunction in Behçet's patients. However, further comprehensive studies are needed to determine the long-term effects of nebivolol.
authors.affiliation: Clinic of Cardiology, Niğde State Hospital, Niğde, Turkey.
authors.forename: Hasan
authors.initials: H
authors.lastname: Akkaya
authors.forename: Omer
authors.initials: O
authors.lastname: Sahin
authors.forename: Murat
authors.initials: M
authors.lastname: Borlu
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Oğuzhan
authors.forename: Mustafa Serkan
authors.initials: MS
authors.lastname: Karakaş
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000503:physiopathology*; D001578:Benzopyrans / Q000494:pharmacology*; D001916:Brachial Artery / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D004983:Ethanolamines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D000068577:Nebivolol; D011446:Prospective Studies; D012039:Regional Blood Flow; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D001578:Benzopyrans; D004983:Ethanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol